IPP Bureau
Novartis secures new approval in China for Cosentyx in pediatric psoriasis
By IPP Bureau - August 18, 2021
Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
Novartis announces positive results from Phase 3 trials of Beovu for diabetes
By IPP Bureau - August 18, 2021
Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
Real world data from Paraguay shows one-shot Sputnik Light vaccine has high safety and efficacy of 93.5 %
By IPP Bureau - August 18, 2021
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik
Apollo Children’s hospital saves new born with rare brain vascular malformation
By IPP Bureau - August 18, 2021
Seen in 1 in 3 million births, the malformation was detected at the antenatal stage during the mother's pregnancy
Test At Home (TAH), offers convenient saliva-based testing for Covid-19
By IPP Bureau - August 18, 2021
TAH is now undergoing regulatory clearance and final quality control procedures for the swab deployment in India, EU, Singapore, UK, US, Australia and others for COVID-19 testing
Pfizer & BioNTech submits Phase 1 data to US FDA for booster dose Covid-19
By IPP Bureau - August 17, 2021
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
European Commission mandates InferVision AI to monitor Covid-19 variants
By IPP Bureau - August 17, 2021
InferVision's AI applications have been developed to quickly and accurately analyse signs of pulmonary infections from regular chest CT images. These images are processed to indicate ground-glass opacity and high tissue density, which are key findings of viral pneumonia caused by the coronavirus
Suven Life Sciences announces Phase 3 clinical trial of Masupirdine
By IPP Bureau - August 17, 2021
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
Lupin receives tentative U.S. FDA approval for Brivaracetam tablets
By IPP Bureau - August 17, 2021
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
.jpg "India-Sweden Healthcare innovation challenge launched")
India-Sweden Healthcare innovation challenge launched
By IPP Bureau - August 17, 2021
The focus of this year’s challenge is to find solutions within Covid management and treatment of cardiovascular, renal, neuro, cancer and lung diseases
One more lab approved for batch-testing and release of Covid-19 vaccines
By IPP Bureau - August 17, 2021
National Institute of Animal Biotechnology, Hyderabad can now conduct quality checks and consequent lot release of Covid-19 vaccines
Centre allocates Rs 267.35 crores to Kerala for Covid response
By IPP Bureau - August 17, 2021
Rs one crore for each district to create medicine pool and support Centre of Excellence for Telemedicine
SCHOTT and Serum Institute announce JV for pharma packaging
By IPP Bureau - August 17, 2021
Serum buys 50 per cent stake in Indian joint venture of SCHOTT Kaisha
Indian pharma’s vaccine opportunity at US $ 10-11 billion
By IPP Bureau - August 17, 2021
Domestic market and developing countries will need doses of Indian vaccines
Zydus Cadila receives tentative approval for cancer drug
By IPP Bureau - August 17, 2021
Lenalidomide is used to treat cancer and also some anaemia disorders
